Two Sigma Investments
XLO icon

Two Sigma Investments’s Xilio Therapeutics XLO Stock Holding History

Two Sigma Investments’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,431
Closed -$39.7K – 4965
2025
Q4 		$39.7K Sell
4,431
-1,840
-29% -$19.3K ﹤0.01% 3956
2025
Q3 		$74K Buy
6,271
+697
+13% +$6.98K ﹤0.01% 3506
2025
Q2 		$53.1K Sell
5,574
-431
-7% -$4.55K ﹤0.01% 3060
2025
Q1 		$60.9K Buy
6,005
+5,232
+677% +$65.8K ﹤0.01% 3028
2024
Q4 		$10.3K Buy
773
+31
+4% +$426 ﹤0.01% 3134
2024
Q3 		$8.18K Buy
+742
New +$9.11K ﹤0.01% 3053

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments's XLO Position: Q1 2026 in Review

Two Sigma Investments sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 4,431 shares — an estimated $39.7K sold.

Two Sigma Investments first reported a position in XLO in Q3 2024 and held it in 6 quarters. The position peaked at $74K in Q3 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Two Sigma Investments reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Investments sold 4,431 Xilio Therapeutics shares in Q1 2026, an estimated $39.7K.
  • Two Sigma Investments first reported a position in Xilio Therapeutics in Q3 2024 and held it in 6 quarters.
  • Two Sigma Investments's Xilio Therapeutics position peaked at $74K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.